Home/Pipeline/Ciltacabtagene autoleucel (Carvykti)

Ciltacabtagene autoleucel (Carvykti)

Relapsed/Refractory Multiple Myeloma

Approved / Phase 3ActiveMultiple (e.g., NCT04181827, NCT04923893)

Key Facts

Indication

Relapsed/Refractory Multiple Myeloma

Phase

Approved / Phase 3

Status

Active

Company

Genscript Biotech

About Genscript Biotech

Founded in 2002, GenScript Biotech has evolved from a gene synthesis pioneer into a $24+ billion market cap global platform, serving over 200,000 clients worldwide. Its mission is to make biology easier and accelerate the transition from discovery to therapy. The company's strategy leverages its dominant Life Science Services segment as a powerful funnel to drive growth in its high-value Biologics CDMO and Cell Therapy businesses, creating a unique, synergistic ecosystem.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Relapsed/Refractory Multiple Myeloma Drugs

Drug	Company	Phase	Status
Aplidin (plitidepsin)	PharmaMar	Approved (Conditional - AU)	R&D
CAR T-Cell Therapy Program	Dr. Reddy's Laboratories	Development	Active
inobrodib + Pd (InoPd)	CellCentric	Phase 1/2	Active
TECVAYLI + DARZALEX FASPRO	Johnson and Johnson Innovative Medicine	Approved	Active
HDP-101	Heidelberg Pharma	Phase 1/2a	Active
CT053	CARsgen Therapeutics	Phase 1b/2	Active
P-BCMA-ALLO1	Poseida Therapeutics	Phase 1	Active
ABBV-383	AbbVie	Phase 1	Active
Blenrep (belantamab mafodotin)	GSK plc	Phase III	Active
bri-cel (BAY 2413334)	Bayer	Phase I	Active, recruiting
CAR-T Cell Therapy	Dr. Reddy's Laboratories	Discovery/Development	Active
Anitocabtagene Autoleucel (anito-cel)	Arcellx	Phase 2	Active, Partnered